During the corresponding time, 4d Molecular Therapeutics Inc recorded a revenue increase by 25106.67 % year on year, sequentially revenue grew by 24.09 %. While revenue at the 4d Molecular Therapeutics Inc 's corporate clients
Transformative Advances in Cystic Fibrosis Treatment: 4D Molecular Therapeutics and the Future of 4D-710 Cystic fibrosis (CF) is a life-threatening genetic disorder that primarily affects the lungs, leading to severe respiratory complications and necessitating ongoing, advanced therapeutic interventions. With the advent of targeted therapies in the last decade, the landscape of CF treatment is evolving rapidly. Among the pioneering efforts in this field is 4D Molecular Therapeutics (4DMT), a biotechnology company that is pushing the boundaries of treatment modalities through the development of disease-specific therapeutics. Recently, the announcement of further funding and support for 4D-710 has brought ren...
4DMT Expands Leadership and Vision in Ophthalmology Amid Significant Revenue Growth Emeryville, Calif. August 5, 2024 4D Molecular Therapeutics (Nasdaq: FDMT), a frontrunner in the realm of genetic medicines, has made strategic advancements in its expansion within the ophthalmology market through significant senior management appointments and the establishment of a dedicated Ophthalmology Advisory Board. This initiative underscores 4DMT s commitment to leveraging innovative genetic therapies to address prevalent ocular diseases and improve patient outcomes.The leadership enhancements feature the appointments of Dhaval Desai, PharmD, as Chief Development Officer; Christopher Simms as Chief Commercial Of...
A Promising Leap Forward in Cystic Fibrosis Treatment: Interim Data from 4DMT s AEROW Clinical Trial Cystic fibrosis (CF) is a debilitating genetic disorder that severely impacts lung function. Traditional therapeutic strategies have seen limited success, particularly for patients ineligible or intolerant to CF modulators. However, 4D Molecular Therapeutics (4DMT; Nasdaq: FDMT) is making significant strides in the fight against CF with their innovative genetic medicine, 4D-710. Recent announcements from the company reveal promising interim data from their Phase 1/2 AEROW clinical trial, aimed at treating CF lung disease through an aerosolized delivery method. These updates have significant implications for...
As the globe continues to battle a range of diseases, advancements made in the field of genetic medicines have been critical in altering the course of disease management. In cognizance of this, 4D Molecular Therapeutics, a clinical-stage genetic medications thought-leader dedicated to harnessing the capabilities of genetic medicine to tackle major massive market illnesses, has recently revealed encouraging interim data derived from the randomized Phase 2 PRISM clinical trial that assessed intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.The results, primarily centered around patients displaying severe disease activity with a high treatment burden, was announced at the highly e...
In an outstanding demonstration of biotech synergy, 4D Molecular Therapeutics(Nasdaq: FDMT, 4DMT), a trailblazing clinical-stage genetic medicines enterprise, and Arbor Biotechnologies, Inc., an innovative gene editing firm, have announced a strategic partnership. This collaboration intends to accelerate the development of new AAV-based gene-editing therapies for central nervous system (CNS) diseases for populations with high unmet medical needs, heralding a new approach in treating both rare and common diseases.4D Molecular Therapeutics, based in Emeryville, California, has established itself as a leader in the biotech industry, unlocking the profound potential of genetic medicine in addressing large market...
4D Molecular Therapeutics (4DMT), a renowned clinical-stage genetic medicines company, has recently announced that its investigational genetic medicine candidate, 4D-150, has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). This groundbreaking designation marks a significant milestone in developing an effective treatment for wet age-related macular degeneration (wet AMD), an eye disease that causes vision loss in millions of individuals worldwide.Addressing Unmet Medical Need:The FDA granted the RMAT designation to 4D-150 due to its potential to address the unmet medical need within the wet AMD population. Wet AMD is a progressive condit...
Sources:
4d Molecular Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 4d Molecular Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on 4d Molecular Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
175.83 %